Proteomic and inflammation alterations (such as neurotrophins, IL-10, and glutathione peroxidase) combined with ML technologies were able to distinguish healthy controls from patients with bipolar disorders or schizophrenia. The gene discussed is BDNF; the disease is schizophrenia.